A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Registrational; Therapeutic Use
- Acronyms EXPLORER-HCM
- Sponsors MyoKardia
- 08 Mar 2018 According to a MyoKardia media release, data from the PIONEER-HCM study will inform the starting dose and guide dose-adjustment for this study.
- 07 Feb 2018 According to a Sanofi media release, the company expects to initiate this study in Q2 2018.
- 13 Dec 2017 According to a Sanofi media release, the company expects to initiate this study in 2018.